» Articles » PMID: 11779601

Reproductive Health in Individuals with Homozygous Beta-thalassemia: Knowledge, Attitudes, and Behavior

Overview
Journal Fertil Steril
Date 2002 Jan 10
PMID 11779601
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To review the reproductive health knowledge, attitudes, and behaviors of persons with homozygous beta-thalassemia.

Design: Case-control study.

Setting: Patients treated at a tertiary hospital and community-based healthy controls.

Participant(s): One hundred and thirty persons, 16 years of age or older, who had homozygous beta-thalassemia and were attending hospital for regular blood transfusion, and 99 demographically matched persons without thalassemia. ASSESSMENT TOOL: Reproductive health questionnaire.

Result(s): 104 (80%) persons with homozygous beta-thalassemia completed the questionnaire and were compared with 99 controls. Persons with homozygous beta-thalassemia were as likely as healthy peers to be in a relationship, employed full-time, sexually active, and using contraception and to have had children. Hypogonadotrophic hypogonadism was present in 55 (52.8%) patients, 46 (83.6%) of whom were compliant with hormone replacement therapy. Understanding of genetics and reproductive potential was suboptimal among persons with homozygous beta-thalassemia, and this group had a higher rate of unplanned pregnancy.

Conclusion(s): This study suggests that with optimal therapy, most young adults with homozygous beta-thalassemia can achieve reproductive, sexual, and social experiences similar to those of their healthy peers.

Citing Articles

Homozygous Delta-Beta Thalassaemia With Alpha Thalassaemia and Erythrocytosis- a Rare Case Report.

Shokr H, Marwah M, Siddiqi H, Wright C, Marwah S Br J Biomed Sci. 2024; 81:13663.

PMID: 39640193 PMC: 11617142. DOI: 10.3389/bjbs.2024.13663.


A Multicenter ICET-A Study on Age at Menarche and Menstrual Cycles in Patients with Transfusion-Dependent Thalassemia (TDT) who Started Early Chelation Therapy with Different Chelating Agents.

Di Maio S, Marzuillo P, Daar S, Kattamis C, Karimi M, Forough S Mediterr J Hematol Infect Dis. 2023; 15(1):e2023058.

PMID: 38028391 PMC: 10631706. DOI: 10.4084/MJHID.2023.058.


Experiences, Knowledge Gaps and Information Needs of Women in Australia with Transfusion Dependent Thalassaemia in Regard to Fertility and Pregnancy.

Matthiesson H, Berdoukas V, Briganti E Matern Child Health J. 2023; 27(11):1961-1967.

PMID: 37273135 PMC: 10564654. DOI: 10.1007/s10995-023-03683-8.


Fetal factors disrupt placental and maternal iron homeostasis in murine β-thalassemia.

Yu Y, Woloshun R, Lee J, Ebea P, Zhu S, Nemeth E Blood. 2023; 142(2):185-196.

PMID: 37146247 PMC: 10352602. DOI: 10.1182/blood.2022018839.


Consequences of -Thalassemia or Sickle Cell Disease for Ovarian Follicle Number and Morphology in Girls Who Had Ovarian Tissue Cryopreserved.

Mamsen L, Kristensen S, Pors S, Botkjaer J, Ernst E, Macklon K Front Endocrinol (Lausanne). 2021; 11:593718.

PMID: 33519708 PMC: 7844814. DOI: 10.3389/fendo.2020.593718.